Biotech: Page 19
-
Daniel Tadevosyan via Getty Images
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers climbed.
By BioPharma Dive staff • Sept. 24, 2024 -
Permission granted by CRI
Q&AWant better cancer treatments? Make biopharma more like Silicon Valley
In an interview with PharmaVoice, Alicia Zhou, the new head of the nonprofit Cancer Research Institute, expressed a desire to foster deeper partnerships between scientists and the pharmaceutical industry.
By Michael Gibney • Sept. 24, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Permission granted by Biogen
Biogen, UCB get the lupus data they’ve waited two decades for
The companies now plan on starting this year another large study of their medicine, dapirolizumab pegol, in the hopes that they can confirm its safety and effectiveness to drug regulators.
By Jacob Bell • Sept. 24, 2024 -
Courtesy of Biohaven Ltd.
After setback, Biohaven to seek approval of neurological disorder drug
With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.
By Jacob Bell • Sept. 23, 2024 -
Canva/ alexanders-images
Sponsored by PanalgoData advancements are finally unlocking drug safety during pregnancy
Dr. Meg Richards from Panalgo discusses how real-world data is unlocking advancements in drug safety during pregnancy.
By Meg Richards, PhD, MPH, Executive Director, Strategic Solutions & Consulting Services, Panalgo • Sept. 23, 2024 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines
The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said CEO Emmanuel Hanon.
By Delilah Alvarado • Sept. 23, 2024 -
Daniel Tadevosyan via Getty Images
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
By BioPharma Dive staff • Sept. 20, 2024 -
Courtesy of Roche
Roche’s Xofluza reduces flu transmission in Phase 3 study
According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.
By Delilah Alvarado • Sept. 19, 2024 -
Kimberly White/Getty Images via Getty Images
23andMe’s independent board directors resign
In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future.
By Ricky Zipp • Sept. 19, 2024 -
Craig Barritt / Stringer via Getty Images
Startup from George Church’s lab raises $75M to develop ‘supercell’ medicines
GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.
By Kristin Jensen • Sept. 19, 2024 -
Anna Moneymaker via Getty Images
Can the Fed’s rate cut change biotech’s ‘new normal’?
Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.
By Ben Fidler • Sept. 19, 2024 -
Permission granted by Roivant Sciences
Roivant dermatology subsidiary to be acquired by Organon
The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.
By Kristin Jensen • Sept. 18, 2024 -
Daniel Tadevosyan via Getty Images
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.
By BioPharma Dive staff • Sept. 18, 2024 -
HadelProductions via Getty Images
Ascendis trial data piles pressure on BioMarin
Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.
By Ned Pagliarulo • Sept. 17, 2024 -
Artur Plawgo via Getty Images
Nura Bio gets $68M, new CEO to advance ‘neuroprotective’ brain drugs
The funding will support mid-stage testing of a drug the company claims holds the potential to treat a range of neurodegenerative conditions.
By Gwendolyn Wu • Sept. 17, 2024 -
JacobH via Getty Images
‘Really exciting times’: One biotech’s view of radiopharma’s boom
Backed by Bristol Myers Squibb, Ratio Therapeutics has a front row seat to the pharmaceutical industry’s pivot into the field of targeted radiation drugs.
By Michael Gibney • Sept. 17, 2024 -
gorodenkoff via Getty Images
Sponsored by SASGenerative AI can enhance pharmaceutical innovation – but are you ready for it?
There’s no doubt that AI and GenAI can speed up pharmaceutical innovation. But before organizations can jump into the future, it’s crucial to understand the benefits – and the risks – of advanced technology.
By Susan Lenderts, Global Head of Life Sciences, SAS • Sept. 16, 2024 -
Permission granted by QIAGEN
Sponsored by QIAGEN Digital InsightsEasy GxP compliance for NGS data – is it even possible?
NGS is changing the landscape for GxP compliance. How can you adapt?
Sept. 16, 2024 -
Daniel Tadevosyan via Getty Images
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into radiopharmaceuticals and Mene Pangalos joined Biogen's board.
By BioPharma Dive staff • Sept. 13, 2024 -
Spencer Platt via Getty Images
Three biotechs raise $700M in rare burst of IPO activity
Bicara Therapeutics, Zenas BioPharma and MBX Biosciences each priced upsized IPOs in the busiest week for biotech stock sales since February.
By Ben Fidler • Sept. 12, 2024 -
Jacob Bell/BioPharma Dive
Moderna to cut costs, trim pipeline in R&D revamp
As part of a broad restructuring, the company plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a spokesperson told BioPharma Dive.
By Ben Fidler • Sept. 12, 2024 -
AndreasReh via Getty Images
F2G raises $100M to bring antifungal drug back to FDA
The funding, from AMR Action Fund and others, will help U.K.-based F2G complete late testing of a treatment that the FDA rejected one year ago.
By Delilah Alvarado • Sept. 12, 2024 -
Daniel Tadevosyan via Getty Images
GSK discontinues herpes vaccine; Roivant launches new ‘vant’ around hypertension drug
The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity drug data and Lilly appointed a company veteran as its new CFO.
By BioPharma Dive staff • Sept. 11, 2024 -
Maximusnd via Getty Images
Bain closes $3B biotech fund amid flurry of startup buyouts
The fund is Bain’s fourth and follows several recent acquisitions of some of its portfolio companies, among them Jnana Therapeutics and EyeBio.
By Delilah Alvarado • Sept. 10, 2024 -
Win McNamee via Getty Images
House backs bill restricting China role in US biotech
The Biosecure Act, which limits contracts with WuXi AppTec, WuXi Biologics and three other companies, still needs Senate support to advance.
By Jonathan Gardner • Sept. 10, 2024
Previous
